Pushback escalates after drug companies restrict 340B drug discounts

After AstraZeneca’s move to stop selling discounted drugs to safety net providers through contract pharmacies, patient advocates took the drugmaker to task.

Outside AZ’s Delaware headquarters, protestors blasted the company’s recent decision to restrict the sale of discounted meds through contract pharmacies under the federally mandated 340B Drug Pricing Program. The program requires companies to discount medicines to hospitals and clinics that serve disadvantaged communities.

Continue reading on Fierce Pharma.